Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.32 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.30 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.30 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.33 |
| ▸ | LIPC | P11150 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.30 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL4132143 | 1.00 | CYP2A6 (0.35) | CYP2A6LIPGLIPCKDM4EMEN1 | |
| Fumaric Acid SCHEMBL3695553 | 0.95 | CYP2A6 (0.32) | CYP2A6LIPGLIPC | |
| Fumaric Acid SCHEMBL3646703 | 0.83 | KDM4E (0.36) | CYP2A6LIPGKDM4EMEN1ALDH1A1 | |
| Fumaric Acid SCHEMBL3646707 | 0.83 | KDM4E (0.36) | CYP2A6LIPGKDM4EMEN1ALDH1A1 | |
| Fumaric Acid SCHEMBL4130276 | 0.82 | CYP2A6 (0.34) | CYP2A6MEN1KMT2ACYP2D6 | |
| Fumaric Acid SCHEMBL4130268 | 0.82 | CYP2A6 (0.34) | CYP2A6MEN1KMT2ACYP2D6 | |
| Fumaric Acid SCHEMBL4135457 | 0.81 | NAMPT (0.37) | CYP2A6KDM4EMEN1ALDH1A1KMT2A | |
| Fumaric Acid SCHEMBL4135452 | 0.81 | NAMPT (0.37) | CYP2A6KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL4132145 | 0.80 | HCAR2 (0.32) | LIPGLIPC | |
| Fumaric Acid SCHEMBL4120332 | 0.80 | CYP2A6 (0.33) | CYP2A6LIPGKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | MEN1 1910/4885KMT2A 4776/4885ADRA2A 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.